All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Ibrutinib Receives Additional Breakthrough Designation for CLL

April 8th 2013

After receiving breakthrough therapy designation from the FDA for the treatment of two B-cell malignancies earlier this year, ibrutinib has received an additional breakthrough designation.

Melanoma

April 8th 2013

Melanoma is on the rise in children and teenagers.

Medicare Reimbursement Cuts Caused by Sequestration Begin to Take Effect

April 4th 2013

As a result of sequestration-related federal budget cuts, Medicare reimbursement has been reduced by 2% across the board, with the reduction affecting a number of services offered to cancer patients.

OncLive Collaborates With Renowned Cancer Centers

April 2nd 2013

Dana-Farber Cancer Institute and Seattle Cancer Care Alliance Join OncLive's Strategic Alliance Partnership Program.

Good News for Cancer Survivorship

March 25th 2013

The number of cancer survivors in the US continues to rise.

Novel Oncolytic Virus Effective in Melanoma

March 22nd 2013

The novel immunotherapy talimogene laherparepvec has become the first oncolytic virus to successfully complete a phase III trial in advanced melanoma.

Novel Compound LDK378 Receives Breakthrough Designation for ALK+ NSCLC

March 15th 2013

The compound LDK378, a highly selective inhibitor of ALK, has been granted "Breakthrough Therapy Designation" by the FDA for the treatment of patients with ALK-positive metastatic non-small cell lung cancer.

Lymphoseek Approved to Help Detect Lymph Nodes in Breast Cancer and Melanoma

March 13th 2013

The FDA approved the radioactive diagnostic imaging agent technetium Tc 99m tilmanocept (Lymphoseek Injection) to identify lymph nodes for potential removal in patients with breast cancer or melanoma.

Nurses' Educational Preparation and Patient Outcomes

March 12th 2013

RNs with baccalaureate degrees provide the best post-surgical care.

Electronic Medical Record Adoption

March 6th 2013

A money-losing proposition for most practices.

Sequestration Takes Effect, Imposes Major Cuts to Cancer Research and Care

March 2nd 2013

Two months after temporarily delaying a package of budget cuts and tax increases, federal lawmakers allowed the changes to automatically take effect by failing to agree on an alternative plan.

Regorafenib Approved to Treat GIST

February 25th 2013

The FDA approved regorafenib for the treatment of gastrointestinal stromal tumors that cannot be removed surgically and no longer respond to other FDA-approved treatments for the disease.

Lung Cancer Risk Prediction Model

February 25th 2013

Using different selection criteria for screening is superior to currently recommended criteria.

T-DM1 Approved for HER2-Positive Metastatic Breast Cancer

February 22nd 2013

The FDA has approved ado-trastuzumab emtansine, also known as T-DM1, for HER2-positive metastatic breast cancer.

Colorectal Surgery

February 19th 2013

A consensus panel issues a set of discharge warning instructions regarding colorectal surgery.

FDA Gives Radium-223 Priority Review Status

February 13th 2013

Radium Ra 223 Dichloride will be considered as a treatment for patients who have castration-resistant prostate cancer with bone metastases under the FDA's priority review program.

Ibrutinib Receives Breakthrough Designations for Mantle Cell Lymphoma and WaldenstrÃ¶m's Macroglobulinemia

February 13th 2013

The investigational agent ibrutinib was granted "Breakthrough Therapy Designations" by the FDA as a singular therapy for a pair of B-cell malignancies: relapsed or refractory mantle cell lymphoma and WaldenstrÃ¶m's macroglobulinemia.

Palifosfamide Trial Reaches Target for PFS Events

February 12th 2013

The phase III PICASSO 3 trial examining palifosfamide plus doxorubicin in metastatic soft tissue sarcoma has reached its goal for progression-free survival events.

Pomalidomide Approved for Relapsed or Refractory Multiple Myeloma

February 8th 2013

The FDA announced the approval of pomalidomide for the treatment of multiple myeloma after patients have relapsed or become refractory to other cancer drugs.

Generic Doxil Approved, Expected to Help Resolve Shortage

February 4th 2013

The FDA has announced the approval of the first generic version of Doxil, which is expected to help alleviate a shortage of the drug that has continued since November 2011.